Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report

American Journal of Hematology

Volumn 92, Issue 3, 2017, Pages E34-E35

  Rimsans, Jessica ^a   Rhoten, Megan ^a   Sylvester, Katelyn ^a   Singh, Steve K ^a   Connors, Jean M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CREATININE; DABIGATRAN; HEMOGLOBIN; HEPARIN; IDARUCIZUMAB; INOTROPIC AGENT; PROTAMINE; MONOCLONAL ANTIBODY;

ACUTE HEART FAILURE; ADULT; ANTICOAGULATION; ATRIAL FIBRILLATION; BLOOD CLOTTING DISORDER; CARDIOPULMONARY BYPASS; CASE REPORT; CEREBROVASCULAR ACCIDENT; CONGESTIVE CARDIOMYOPATHY; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HEMATOCRIT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERNATIONAL NORMALIZED RATIO; LETTER; MIDDLE AGED; MORNING DOSAGE; OPERATION DURATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; THROMBOCYTE COUNT; PATHOPHYSIOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARDIOMYOPATHY, DILATED; DABIGATRAN; FEMALE; HEART TRANSPLANTATION; HUMANS; MIDDLE AGED;

EID: 85011101756     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24638     Document Type: Letter

References (8)

1. Chai-Adisaksopha C, Hillis C, Isayama T, et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015;13:2012–2020.
2. Levy JH. Discontinuation and management of direct-acting anticoagulants for emergency procedures. Am J Emerg Med. 2016;16:S0735–S6757.
3. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
4. Vanassche T, Greinacher A, Verhamme P. Reversal of dabigatran by idarucizumab: when and how? Expert Rev Hematol. 2016;9:519–528.
5. Demeyere R, Gillardin S, Arnout J, et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99:251–260.
6. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al.; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–1141.
7. Ageno W, Buller HR, Falanga A, et al. Managing reversal of direct oral anticoagulants in emergency situations. Thromb Haemost. 2016;116:5.
8. Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39:395.